A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95), Alone and in Combination With Dacarbazine, in Subjects With Stage IV Melanoma

Trial Profile

A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95), Alone and in Combination With Dacarbazine, in Subjects With Stage IV Melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Dacarbazine (Primary) ; Intetumumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 14 Jul 2011 Actual end date added Feb 2009 as reported by ClinicalTrials.gov.
    • 12 Jul 2011 Phase II results published in the British Journal of Cancer.
    • 12 Jul 2011 Primary endpoint 'Progression-free-survival' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top